Taiji Group (600129.SH): Digoxin Injection passes the consistency evaluation of generic drugs.

Tencent Finance APP News, Taiji Group (600129.SH) announced that recently, the company's controlling subsidiary, Southwest Pharmaceutical Co., Ltd. (hereinafter referred to as Southwest Pharmaceutical), received the "Drug Supplement Application Approval Notification" from the National Medical Products Administration for Digoxin Injection (Specification: 2ml:0.5mg). Southwest Pharmaceutical's Digoxin Injection has passed the evaluation of generic drug quality and efficacy consistency.